



SYMPOSIUM 7. RWD/RWE application in regulatory and reimbursement decision makings

Moderators

Bor-Sheng Ko, President, Taiwan Society of Pharmaco-economics and Outcome Research; National Taiwan University Cancer Center, Taiwan



Dr. Bor-Sheng Ko is now an associate professor and the director of the Department of Hematological Oncology, National Taiwan University Cancer Center. He is also an attending physician in in the Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, and the director of Tai-Cheng Cell Therapy Center, National Taiwan University. He received his medical degree from the National Taiwan University College of Medicine in 1995, after which he completed clinical training for internal medicine and Hematology/Hematopoietic stem cell transplant (HSCT) fellowship in National Taiwan University Hospital. He then received PhD degree from the Institute of Clinical Medicine in the National Taiwan University College of Medicine in 2011. From 2013 to 2019, he was assigned as the Secretary-General of Taiwan Society of Blood and marrow Transplantation (TBMT), and was elected as the President of TBMT form 2019 to 2022. He is the president of Taiwan Society of Pharmacoeconomics and Outcome Research (TaSPOR/ISPOR Taiwan Chapter) since 2018, and still the execute director of TBMT.

Fei-Yuan Sharon Hsiao, National Taiwan University, Taiwan



Dr. Fei-Yuan Sharon Hsiao is currently the professor and director of Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University. As a pharmacoepidemiologist by training, Dr. Hsiao has extensive experiences in real-world studies focusing on post-marketing surveillance, gerontology and several clinical fields. She has involved in several projects at the national level, including building and maintaining the pharmacovigilance system in Taiwan, funded by Taiwan's Food and Drug Administration (TFDA). Dr. Hsiao has authored more than 120 peer-reviewed journal papers. With great honor, Dr. Hsiao was awarded the Ronald D. Mann Best Paper Award from the International Society of Pharmacoepidemiology (ISPE) in 2016. In 2019, she was awarded the Wu Da-Yu memorial award from the Ministry of Science and Technology, Taiwan, for her continuous academic devotion and achievement in researches of public health. Dr. Hsiao has devoted herself in public policy for several years. Dr. Hsiao also supports several professional organizations. She is currently the



executive director of Taiwan Society for Pharmacoeconomics and Outcome Research (TaSPOR) and the director of Taiwan Association of Integrated Care.

Speakers

Belle Chou, Global Integrated Access Strategy Lead, Amgen Inc.



Belle worked in the pharmaceutical industry for around 14 years. She started her career from the pharmaceutical industries in Taiwan since 2008. She worked with Academia, using NHRI database to do epidemiology analysis, understand local treatment patterns in several disease areas, in order to support reimbursement submissions in Taiwan. Belle moved to Singapore in 2016, started her regional experience in Novartis Oncology Asia-Pacific team, supporting countries in AP region, including Korea, Taiwan, Singapore, Hong Kong, Malaysia, Thailand, Vietnam and Indonesia for pricing and reimbursement strategy development. She joined Amgen in 2019 from Japan & Asia-Pacific region, currently based in Hong Kong, and is now working in Amgen global team. Belle is a pharmacist, graduated from graduate institute of Public Health, National Taiwan University.

Isao Kamae, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan



Isao Kamae, Former ISPOR President 2021-2022, is Japan's foremost expert in HTA and pharmacoeconomics, serving as a project professor of HTA, The University of Tokyo, and a research director, The Canon Institute for Global Studies, Tokyo, since 2012. He was the first Japanese to be awarded a Doctor of Public Health in health decision sciences, Harvard University, in 1995, and had international experiences including an advisory expert for WHO and OECD. He previously worked in medical schools and the national university hospitals in Japan with more than 200 papers and 30 books publication. He was awarded ISPOR Distinguished Service Award four times for great contributions to ISPOR, regarding the first Asia-origin ISPOR Board of Director 2004-2006, the founding President of ISPOR Japan Chapter in 2005-2009, a founder for the ISPOR Asia Consortium, and ISPOR Asia-Pacific Conference. In 2019 he published an English textbook on "Health Technology Assessment in Japan", which made an impact on global community of HTA.



SeungJin Bae, College of Pharmacy, Ewha Womans University, Seoul, Korea



Dr. Bae received her master's and doctoral degree in Health Policy & Management from Harvard School of Public Health, and bachelor of pharmacy from Ewha Womans University, Korea. Her research interests include the value of pharmaceuticals and outcomes research using National Health Insurance claim database. Dr. Bae authored Economic Evaluation guidelines in Korea (2nd & 3rd version), and currently serving the Chair of the Economic Subcommittee of the Pharmaceutical Benefit Coverage Advisory Committee, and the Editorial Board at the BMC Public Health. She was the President of the ISPOR KOREA Chapter (2020-21), and was Head Researcher at the Health Insurance Review and Assessment Service, Korea. Before joining the HIRA, she researched at Harvard Center for Risk Analysis and interned at the United States Congress, Congressional Budget Office.